FDA Approves First-in-Class Drug for Migraine Prevention

Share this post

The human monoclonal antibody erenumab has become the first anti-calcitonin-gene-related peptide (CGRP) treatment to receive FDA approval for the prevention of migraine.
FDA Approvals

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.

Share this post

Be the first to comment

Leave a Reply